Cystic Fibrosis Foundation Announces Investment In Saliogen Therapeutics To Fund Genetic Therapies Research

The Cystic Fibrosis Foundation announced today that it has invested in SalioGen Therapeutics to support the company’s preclinical research into a novel genetic therapy for cystic fibrosis. SalioGen’s Gene CodingTM approach is designed to turn on, turn off, or modify the function of any gene in the genome.